add items to your
binder to email or
print all at once
Items In Binder
Site Lawyers
Mylan's Acquisition of Global Marketing Rights to Once-Monthly Glatiramer Acetate Product through an Investment in and Partnership with Mapi Pharma

On April 10, 2018, Mylan N.V. (“Mylan”), a global pharmaceutical company, and Mapi Pharma Ltd. (“Mapi Pharma”), a fully integrated, clinical late stage biopharmaceutical company, announced that they will partner on the development and commercialization of GA Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis. Mylan is acquiring global marketing rights to the product. Cravath is representing Mylan in connection with the transaction.

The Cravath team is led by partners Aaron M. Gruber and Mark I. Greene and includes associate Alex L. Winkelman on M&A matters; partner David J. Kappos and associate Sean M. Gholz on intellectual property matters; and partner Kara L. Mungovan and associate Damien J. Rose on tax matters.